Extreme bipolar androgen therapy with darolutamide and testosterone cypionate in patients with metastatic castration-resistant prostate cancer: ExBAT (LACOG 0620) trial.

被引：0
|
作者：
Velho, Pedro H. Isaacsson
Girardi, Daniel da Motta
Soares, Andrey
Jardim, Denis Leonardo Fontes
Maluf, Fernando Cotait
Morbeck, Igor Alexandre
Dias, Mariane Fontes
Souza, Vinicius Carrera
E Silva, Adriano Goncalves
de Jesus, Rafaela Gomes
Rebelatto, Taiane Francieli
Bastos, Diogo Assed
机构：
[1] Hosp Moinhos De Vento, Porto Alegre, RS, Brazil
[2] Hosp Sirio Libanes, Brasilia, DF, Brazil
[3] Hosp Israelita Albert Einstein, Sao Paulo, SP, Brazil
[4] Grp Oncoclin, Sao Paulo, SP, Brazil
[5] Hosp Sirio Libanes, Sao Paulo, SP, Brazil
[6] Hosp Benefencia Portuguesa, Sao Paulo, SP, Brazil
[7] Grp Oncoclin, Rio De Janeiro, RJ, Brazil
[8] Hosp Alianca, Oncol DOr, Salvador, BA, Brazil
[9] Inst Canc & Transplante Curitiba ICTr, Curitiba, PR, Brazil
[10] Latin Amer Cooperat Oncol Grp LACOG, Porto Alegre, RS, Brazil
[11] Hosp Sirio Libanes, Sao Paulo, SP, Brazil
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS276
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial
    Mark C. Markowski
    Mary-Ellen Taplin
    Rahul Aggarwal
    Laura A. Sena
    Hao Wang
    Hanfei Qi
    Aliya Lalji
    Victoria Sinibaldi
    Michael A. Carducci
    Channing J. Paller
    Catherine H. Marshall
    Mario A. Eisenberger
    David E. Sanin
    Srinivasan Yegnasubramanian
    Carolina Gomes-Alexandre
    Busra Ozbek
    Tracy Jones
    Angelo M. De Marzo
    Samuel R. Denmeade
    Emmanuel S. Antonarakis
    Nature Communications, 15
  • [2] Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial
    Markowski, Mark C.
    Taplin, Mary-Ellen
    Aggarwal, Rahul
    Sena, Laura A.
    Wang, Hao
    Qi, Hanfei
    Lalji, Aliya
    Sinibaldi, Victoria
    Carducci, Michael A.
    Paller, Channing J.
    Marshall, Catherine H.
    Eisenberger, Mario A.
    Sanin, David E.
    Yegnasubramanian, Srinivasan
    Gomes-Alexandre, Carolina
    Ozbek, Busra
    Jones, Tracy
    De Marzo, Angelo M.
    Denmeade, Samuel R.
    Antonarakis, Emmanuel S.
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [3] Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer
    Michael T. Schweizer
    Roman Gulati
    Todd Yezefski
    Heather H. Cheng
    Elahe Mostaghel
    Michael C. Haffner
    Radhika A. Patel
    Navonil De Sarkar
    Gavin Ha
    Ruth Dumpit
    Brianna Woo
    Aaron Lin
    Patrick Panlasigui
    Nerina McDonald
    Michael Lai
    Katie Nega
    Jeannette Hammond
    Petros Grivas
    Andrew Hsieh
    Bruce Montgomery
    Peter S. Nelson
    Evan Y. Yu
    Prostate Cancer and Prostatic Diseases, 2023, 26 : 194 - 200
  • [4] Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer
    Schweizer, Michael T.
    Gulati, Roman
    Yezefski, Todd
    Cheng, Heather H.
    Mostaghel, Elahe
    Haffner, Michael C.
    Patel, Radhika A.
    De Sarkar, Navonil
    Ha, Gavin
    Dumpit, Ruth
    Woo, Brianna
    Lin, Aaron
    Panlasigui, Patrick
    McDonald, Nerina
    Lai, Michael
    Nega, Katie
    Hammond, Jeannette
    Grivas, Petros
    Hsieh, Andrew
    Montgomery, Bruce
    Nelson, Peter S.
    Yu, Evan Y.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2023, 26 (01) : 194 - 200
  • [5] Bipolar androgen therapy for treatment of metastatic castration-resistant prostate cancer: A case series
    Tran, Elizabeth U.
    Ovruchesky, Eric
    Yamamoto, Kyra
    Marley, Samantha
    Song, Alexander
    Pan, Elizabeth
    Lee, Aaron M.
    Herchenhorn, Daniel
    Denmeade, Sam
    Antonarakis, Emmanuel S.
    Markowski, Mark
    Mckay, Rana R.
    PROSTATE, 2024,
  • [6] A new androgen receptor antagonist Darolutamide for patients with non-metastatic castration-resistant prostate cancer
    Kesch, C.
    Hadaschik, B. A.
    UROLOGE, 2019, 58 (10): : 1217 - 1218
  • [7] Darolutamide for non-metastatic, castration-resistant prostate cancer
    Burki, Talha
    LANCET ONCOLOGY, 2019, 20 (03): : E139 - E139
  • [8] Sequential therapy with darolutamide in patients with non-metastatic castration-resistant prostate cancer resistant to enzalutamide or apalutamide
    Fujmoto, Saizo
    Fujita, Kazutoshi
    Nishimoto, Mitsuhisa
    Hamaguchi, Mamoru
    Kuwahara, Ken
    Hashimoto, Mamoru
    Adomi, Shogo
    Minami, Takafumi
    Nozawa, Masahiro
    Yoshimura, Kazuhiro
    Uemura, Hirotsugu
    CANCER MEDICINE, 2023, 12 (03): : 3176 - 3179
  • [9] Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
    Scott, Lesley J.
    TARGETED ONCOLOGY, 2020, 15 (06) : 791 - 799
  • [10] Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
    Lesley J. Scott
    Targeted Oncology, 2020, 15 : 791 - 799
12345